22 July, 2015 by The TZ Newswire Staff Comments Off on Dolby Laboratories, Inc.’s Quarter: Loud Earnings, Quiet Revenue
Dolby Laboratories, Inc.’s Quarter: Loud Earnings, Quiet Revenue
Despite sluggish revenue growth, the audiophile intends to reward shareholders in other ways.
22 July, 2015 by The TZ Newswire Staff Comments Off on Oceaneering International Earnings Surpass Expectations
Oceaneering International Earnings Surpass Expectations
The deepwater equipment maker still issues a dour second-half outlook.
22 July, 2015 by The TZ Newswire Staff Comments Off on Qualcomm Earnings Get Overshadowed by Strategic Realignment Plans
Qualcomm Earnings Get Overshadowed by Strategic Realignment Plans
The semiconductor company dropped a bombshell on the market by saying it would consider alternatives to its current corporate structure.
22 July, 2015 by The TZ Newswire Staff Comments Off on WSJ: Anthem closes in on pact to buy Cigna
WSJ: Anthem closes in on pact to buy Cigna
Anthem is reportedly close to a deal to buy Cigna for about $48 billion in a move that would reshape the U.S. health insurance landscape.
22 July, 2015 by The TZ Newswire Staff Comments Off on US Government Reinstates Arm Sales To Bahrain Despite Rampant Human Rights Abuses
US Government Reinstates Arm Sales To Bahrain Despite Rampant Human Rights Abuses
Submitted by Mike Krieger via Liberty Blitzkrieg blog,
One of the many destructive myths Americans like to tell themselves is that the U.S. government is a staunch defender of human rights and democracy around the world. In reality, nothing could be further from the truth.
22 July, 2015 by The TZ Newswire Staff Comments Off on The Wall Street Journal: Anthem nears deal to acquire Cigna for $48 billion
The Wall Street Journal: Anthem nears deal to acquire Cigna for $48 billion
Anthem Inc. is nearing a deal to buy Cigna Corp. for more than $48 billion in a transaction that, alongside another recent proposed tie-up of rivals, would reduce the number of companies atop the U.S.
22 July, 2015 by The TZ Newswire Staff Comments Off on Biotech ETFs: 3 Questions For IShares Investing Expert
Biotech ETFs: 3 Questions For IShares Investing Expert
ETF investors in biotechnology stocks may be rattled by the nose-dive of the first heavyweight out of the earnings gate. IShares Nasdaq Biotechnology (IBB), the $10 billion biotech exchange traded fund, has lost 0.8% in the past three trading sessions as Illumina (ILMN) stumbled.